retatrutide glp-1 receptor agonist How Does Work? Triple Explained Retatrutide | GLP-1R/GIPR/GCGR ligand |

Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

After their success in the obesity field, GLP-1 agonists are gaining interest in addiction treatment

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)